Analgesic Effect of Switching From Oral Opioids to a Once-a-Day Fentanyl Citrate Transdermal Patch in Patients With Lung Cancer

Abstract

A new once-a-day fentanyl citrate transdermal patch was developed in Japan. We retrospectively investigated analgesic and adverse effects of this drug in 24 patients with lung cancer. All patients were started on this patch by switching from an oral opioid. The mean pain score before switching was 2.45 (0-5); 48 hours after switching, 15 of the 24 patients showed a decreased pain score and the mean score (2.00) was significantly lower than that before switching. Of the 16 patients who had adverse effects of oral opioids, 7 patients showed improvement in their symptoms after switching. Two patients showed adverse effects of the drug but their symptoms were mild, and no patient required dose decrease. This new transdermal patch could be a useful treatment option for cancer pain.

Keywords

fentanyl citrate analgesic effect face scale lung cancer oral opioid transdermal fentanyl

Get full access to this article

View all access options for this article.

References

Cleeland

Gonin

Hatfield

. Pain and its treatment in outpatients with metastatic cancer. New Engl J Med. 1994;330 (9):592–596.

van den Beuken-van

Everdingen MH

de Rijke

Kessels

Schouten

van Kleef

Patijn

Prevalence of pain in patients with cancer: a systematic review of the past 40 years. Ann Oncol. 2007;18 (9):1437–1449.

Muijsers

Wagstaff

. Transdermal fentanyl: an updated review of its pharmacological properties and therapeutic efficacy in chronic cancer pain control. Drugs. 2001;61 (15):2289–2307.

Mercadante

Porzio

Ferrera

. Sustained-release oral morphine versus transdermal fentanyl and oral methadone in cancer pain management. Eur J Pain. 2008;12 (8):1040–1046.

Payne

Mathias

Pasta

Wanke

Williams

Mahmoud

. Quality of life and cancer pain: satisfaction and side effects with transdermal fentanyl versus oral morphine. J Clin Oncol. 1998;16 (4):1588–1593.

Caraceni

Hanks

Kaasa

. Use of opioid analgesics in the treatment of cancer pain: evidence-based recommendations from the EAPC. Lancet Oncol. 2012;13 (2):e58–68.

Kokubun

Matoba

Hoka

Yamada

Yago

. Relationship between serum fentanyl concentration and trasndermal fentanyl dosage and intra-individual variability in fentanyl concentration after application of fentanyl pathcs in patients with cancer pain. J Pharm Health Care Sci. 2007;33 (3):200–205.

Uchida

Miyazaki

Namiki

. Pharmacokinetic studies of the transdermal patch containing fentanyl citrate (FT-290) in patients with cancer pain. Rinsho-yakugaku. 2010;26:335–351.

Miyazaki

Namiki

Ogawa

. A phase II clinical study of once-a-day fentanyl citrate patch in patients with cancer pain--switching from once-every-three-days fentanyl patch to once-a-day fentanyl citrate patch. Gan to Kagaku Ryoho. 2010;37 (9):1747–1752.

10.

Kress

Von der Laage

Hoerauf

. A randomized, open, parallel group, multicenter trial to investigate analgesic efficacy and safety of a new transdermal fentanyl patch compared to standard opioid treatment in cancer pain. J Pain Symptom Manage. 2008;36:268–279.

11.

Mystakidou

Tsilika

Kouloulias

Kouvaris

Georgaky

Vlahos

. Long-term cancer pain management in morphine pre-treated and opioid naïve patients with transdermal fentanyl. Int J Cancer. 2003;107 (3):486–492.

12.

Donner

Zenz

Tryba

Strumpf

. Direct conversion from oral morphine to transdermal fentanyl: a multicenter study in patients with cancer pain. Pain. 1996;64 (3):527–534.

13.

Tassinari

Sartori

Tamburini

. Adverse effects of transdermal opiates treating moderate-severe cancer pain in comparison to long-acting morphine: a meta-analysis and systematic review of the literature. J Palliat Med. 2008;11 (3):492–501.